Treatment patterns following first-line pertuzumab plus trastuzumab in patients with HER2+metastatic breast cancer in the United States.

被引：1
|
作者：
Mehta, Sandhya
Pavilack, Melissa
Xie, Jipan
Ionescu-Ittu, Raluca
Nie, Xiaoyu
Lei, Yin
Kwong, Jackie
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] AstraZeneca US, Hlth Econ & Outcomes Res, Gaithersburg, MD USA
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Grp Anal Ltee, Montreal, PQ, Canada
[5] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18746
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
    Sandhya Mehta
    Jipan Xie
    Raluca Ionescu-Ittu
    Xiaoyu Nie
    Winghan J. Kwong
    Oncology and Therapy, 2023, 11 : 481 - 493
  • [2] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+?Metastatic Breast Cancer
    Mehta, Sandhya
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Kwong, Winghan J.
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 481 - 493
  • [3] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [4] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [5] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [6] First-line treatment patterns by age for patients (pts) with HER2+metastatic breast cancer (MBC) in the SystHERs registry
    Jahanzeb, M.
    Tripathy, D.
    Hurvitz, S. A.
    O'Shaughnessy, J.
    Mason, G.
    Yardley, D. A.
    Brufsky, A.
    Rugo, H. S.
    Cobleigh, M.
    Swain, S. M.
    Chu, L.
    Antao, V.
    Yoo, B.
    Kaufman, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    DRUGS, 2012, 72 (03) : 353 - 360
  • [8] Treatment Patterns and Associated Outcomes Among Patients with HER2+Metastatic Breast Cancer in the United States
    Lam, Clara
    Della Varghese
    Nordstrom, Beth L.
    Murphy, Brian
    Collins, Jenna
    Mehta, Sandhya
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [10] Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
    Danese, Mark D.
    Masaquel, Anthony
    Santos, Eduardo
    Brammer, Melissa
    Lee, Abraham
    Lalla, Deepa
    VALUE IN HEALTH, 2015, 18 (06) : 876 - 883
12345